

LOTEMAX[®]

(loteprednol etabonate ophthalmic suspension 0.5% w/v)



By the end of March 2017, LOTE[®]MAX[®] Suspension 0.5% w/v (5 mL only) will be discontinued.

LOTEMAX[®] Suspension 0.5% w/v is indicated for the treatment of post-operative inflammation following cataract surgery.¹

At Bausch + Lomb, we dedicate ourselves to protecting and enhancing the gift of sight for millions of people around the world. Our mission is simple yet powerful: Helping you see better to live better.

We continue to develop, manufacture, and market one of the most comprehensive product portfolios in our industry.

Stay tuned as we update our 2017 catalog for Post-Cataract Surgery Care.

Reference: 1. LOTE[®]MAX[®] [Suspension] Product Monograph, Bausch & Lomb Inc., July 25, 2012.

BAUSCH + LOMB

Bausch & Lomb Canada, Vaughan, Ontario L4K 4B4
© Valeant Canada LP
®/™ are trademarks of Bausch & Lomb Incorporated or its affiliates.

Lotemax[®]
loteprednol etabonate
ophthalmic suspension 0.5%